Combination of Garcinia Mangostana extract and fresh Avena Sativa juice for the treatment of inflammations caused by C. acnes.

Description

DOMAINE TECHNIQUE DE L'INVENTION

[0001] The present invention relates to a novel combination comprising an extract of Garcinia mangostana L. and a juice of 'Avena sativa fresh as well as compositions including this combination, particularly for their use in the field of acne, and especially in the treatment of inflammation induced by C . acnes. ETAT DE LA TECHNIQUE

[0002] Acne is a chronic inflammatory skin condition affecting the pilosebaceous unit, leading to the formation of comedones and impacting the face, shoulders, arms, and intertriginous areas. It is the leading cause of the most common dermatoses. It is important not to trivialize this condition and to treat it properly, as it can have debilitating psychosocial consequences, particularly due to scarring.

[0003] Acne is a multifactorial condition. Indeed, various risk factors can lead to the development of acne or exacerbate it. These factors include hormonal influences and genetic predisposition, as well as external environmental factors such as pollution and UV radiation. Finally, lifestyle can also influence the onset or worsening of acne, namely diet and stress. There are several forms of acne. It can initially manifest as simple comedones (blackheads and whiteheads). This is known as comedonal acne. However, these comedonal lesions can also progress to more severe inflammatory lesions: papules, pustules, and nodules. This is referred to as inflammatory acne. It is now established that inflammation is present at all stages of acne, even the earliest, that is, the subclinical stages: this is known as microinflammation.Classically these two forms coexist: this is mixed acne, affecting nearly 60% of acne sufferers.

[0004] Common acne, or acne vulgaris, also called juvenile polymorphic acne, is the most common and comprises four stages: Stage 1, or comedonal or retention acne, is characterized by a large number of open and / or closed comedones and microcysts. Stage 2, or papulopustular acne, is mild to moderate in severity and is characterized by the presence of open and / or closed comedones, microcysts, as well as red papules and pustules. It primarily affects the face and leaves some scarring. Stage 3, or papulocomedonal acne, is more severe and extends to the back, chest, and shoulders. It is accompanied by numerous scars. Stage 4, or nodulocystic acne, presents with nodules and also large, painful, purple pustules. It is accompanied by numerous scars.

[0005] In its mildest form, acne affects almost everyone. Its frequency is highest during puberty, but it can first appear as early as 7 to 9 years old and persist into adulthood, even beyond 40. It is common to suffer from acne even after the age of 25. Acne also affects both men and women. During puberty, under the influence of hormonal secretions, particularly androgens, and also in conjunction with various external factors, there is an overproduction of sebum, known as seborrhea. In individuals predisposed to acne, this environment is conducive to the development of the key acne bacteria. Cutibacterium acnes ( C. acnes (formerly called Propionibacterium acnes This bacterium metabolizes skin triglycerides into irritating fatty acids. awaylipases that attack the follicle wall and surrounding dermis, also produce various enzymes and chemoattractants for phagocytic immune cells, and stimulate the production of pro-inflammatory cytokines by different cell types (sebocytes, keratinocytes, monocytes, in particular) which exacerbate inflammation. This bacterium plays a pivotal role in acne, notably by stimulating the local inflammatory response (Dagnelie et al., Journal of the European Academy of Dermatology 2019, 33(12), 2340-2348). For a long time, it was thought that combating this bacterial species was the priority in acne treatment. The use of various topical antimicrobials is still widely employed today (benzoyl peroxide, erythromycin, triclosan). But recently, researchers have understood that the goal is not to eradicate C . acneswhich is a commensal bacterium, necessary for tissue homeostasis, but to restore balance. Indeed, it is now thought that acne is directly linked to the depletion of the skin microbiota (dysbiosis), which is much less diverse in people suffering from acne than in healthy individuals. Furthermore, the alteration of the skin microbiota leads to changes in skin pH and triggers inflammation.

[0006] Similarly, systemic antibiotic therapy of varying duration was sometimes used in conjunction with treatment, depending on the severity of the condition (tetracyclines, doxycycline). Dermatologists today tend to favor topical anti-inflammatory and sebum-regulating agents.

[0007] Frequent failures were observed with all these treatments, often due to a high proportion of resistant strains of C . acnes.FR 2 938 439 describes the use of an extract of the aerial parts of Avena sativa for the treatment of acne.

[0008] Thus, there is still a need to provide more effective acne treatments that do not present adverse effects in the patient. RESUME DE L'INVENTION

[0009] The present invention relates to an association comprising an extract of Garcinia mangostana and fresh Avena sativa juice, as well as a cosmetic or dermatological composition comprising such an association and at least one cosmetically or dermatologically acceptable excipient.

[0010] The invention also relates to a combination comprising an extract of Garcinia mangostana and fresh Avena sativa juice, as well as a cosmetic or dermatological composition comprising such a combination and at least one excipient that is cosmetically or dermatologically acceptable for use in the treatment of inflammation induced by C . acnes or in the treatment of acne-prone skin.

[0011] Other aspects of the invention are as described below and in the claims. DESCRIPTION DETAILS OF THE INVENTION

[0012] The present invention aims to meet the stated needs. Indeed, the inventors have demonstrated, quite unexpectedly, that the combination of an extract of Garcinia mangostana L. and a juice of 'Avena sativa fresh had the ability to reduce the production of inflammatory cytokines, inflammation being stimulated in the presence of C . acnes.Indeed, the combination of an extract of Garcinia mangostana L. and a juice of 'Avena sativa Fresh has the advantage of acting synergistically on the immuno-inflammatory cascade mediated by C . acnes and thus be useful in the treatment of acne.

[0013] The present invention therefore relates to an association comprising an extract of Garcinia mangostana and a juice of 'Avena sativa fresh, as well as a cosmetic or dermatological composition comprising such a combination and their uses in the treatment of inflammation induced by C . acnes or the treatment of acne-prone skin.

[0014] Garcinia mangostana extract and juice 'Avena sativa Fresh useful within the framework of the present invention may be as described below.

[0015] The term "approximately" as used below means that the value in question may be 10% lower or higher, in particular 5%, and especially 1% higher, than the value indicated. Mangosteen Garcinia extract

[0016] Garcinia mangostana L. is a tropical tree native to Southeast Asia, now cultivated in many tropical countries for its edible fruit, the mangosteen, also called "fruit of the Gods" or "queen of fruits".

[0017] Garcinia mangostanaL. is a dioecious tree that can reach 20 meters in height in the wild. Its leaves are smooth, glossy, leathery, elliptical to elliptical-oblong, measuring 14 to 25 cm by 5 to 10 cm. Their base is cuneate to subrounded, and the apex is shortly acuminate. The rare male flowers are grouped in clusters of 2 to 9 at the tips of twigs, while the female flowers, slightly larger than the male flowers, are solitary or in pairs. The fruit consists of a thick pericarp, pink to very dark purplish when ripe, containing edible white flesh and enclosing 4 to 5 seeds.

[0018] Mangosteen has been known for centuries in traditional Asian medicine for its antioxidant, anti-inflammatory, and antibacterial properties. The pericarp, in particular, is used for skin infections, diarrhea, abdominal pain, urinary tract infections, and bruises. It can also be used to treat fever (Ovalle-Magallanes et al., Food Chem Toxicol 109: 102-122, 2017). In the West, there has also been a surge in popularity for mangosteen over the past decade. Numerous fruit juices made from the flesh and pericarp, dietary supplements, and topical products containing mangosteen are marketed, and recent clinical studies have demonstrated its benefits for various conditions such as weight loss (Udani et al., Nutr J, 8: 48, 2009) and periodontitis (Mahendra et al., J Investig Clin Dent, 8(4), 2017).Mangosteen extracts are also found as active ingredients in several cosmetic products for their anti-aging or slimming properties.

[0019] The mangosteen pericarp is an important source of xanthones, the main ones being α-mangostin and γ-mangostin (Ovalle-magallanes et al., 2017). The mangosteen pericarp also contains tannins, anthocyanins, and sugars. Fruit extracts, and more specifically extracts of mangosteen pericarp with varying levels of xanthone content, have been the subject of numerous pharmacological studies, both in vitro And in vivo. The main activities highlighted are antitumor properties, particularly in the prostate, lung, breast and colon, anti-inflammatory, antioxidant, anti-diabetic, anti-hyperlipidemic and antibacterial properties.

[0020] In the present invention, the plant Garcinia mangostana L. is referred to in abbreviated form as "Garcinia mangostana".

[0021] The term “Garcinia mangostana extract” refers to the product extracted from all or part of the Garcinia mangostana plant.

[0022] The term "extraction product" refers to the product obtained after extraction from a part of the plant using a solvent, called the extraction solvent. This solvent is a product present in the extraction solvent, which may then be in a concentrated or dry form after partial or total evaporation of the extraction solvent. It may be a dry extract.

[0023] For the purposes of this invention, "dry extract" means an extract free from extraction solvent or carrier, or containing only trace amounts of such solvent or carrier.

[0024] Such a dry extract contains only material derived from Garcinia mangostana. It may also contain insignificant traces of extraction solvent. This definition applies particularly when defining the weight content of alpha-mangostin relative to the weight of the dry extract.

[0025] Typically, Garcinia mangostana extract is obtained from one or more aerial parts of the Garcinia mangostana plant such as the fruit, the fruit pericarp, the fruit pulp, the seeds, the leaves, the stems and / or the bark.

[0026] In some embodiments, the extract is obtained from the fruit and / or pericarp of Garcinia mangostana. Advantageously, the extract is obtained from the pericarp of Garcinia mangostana.

[0027] In some embodiments, the extract is obtained from a cell culture of Garcinia mangostana.

[0028] In some embodiments, the extract of Garcinia mangostana, in particular the extract of the pericarps of the fruit of Garcinia mangostana, is a hydro-alcoholic extract, in particular a hydro-ethanolic extract.

[0029] Garcinia mangostana extract, in particular extract from the pericarps of the Garcinia mangostana fruit, is likely to be obtained by a process as described below.

[0030] The Garcinia mangostana extract useful in the context of the present invention can thus be prepared by a preparation process comprising an extraction step of all or part of the Garcinia mangostana plant using a hydrophilic to nonpolar solvent, preferably a moderately polar to nonpolar solvent. The Garcinia mangostana plant or part of the plant used to prepare the Garcinia mangostana extract can be fresh or dried, whole, cut, or ground, and then subjected to an extraction step.

[0031] By "hydrophilic solvent" we mean a solvent chosen from the group consisting in particular of water, subcritical water, water-miscible alcohols such as ethanol, C3 to C5 glycols, glycerol, acetone, and mixtures thereof.

[0032] For the purposes of this invention, "nonpolar solvent" means a solvent chosen for example from heptane, hexane, limonene, halogenated hydrocarbons (chloroform, dichloromethane), supercritical CO2, or a mixture of supercritical CO2 and ethanol.

[0033] For the purposes of this invention, "moderately polar solvent" means a solvent selected from the group consisting in particular of C1 to C5 alcohols, glycols such as propylene glycol, butylene glycol, butanediol, or pentylene glycol, glycerol, acetone, alkyl esters such as ethyl acetate, isopropyl acetate, and water-miscible solvents (for example, a hydro-alcoholic mixture or an acetone / water mixture). This group also includes alternative hydrotropic solvents (amphiphilic molecules soluble in water which, at a sufficient concentration, can extract moderately polar compounds as described in the characterization of the extract).

[0034] In certain embodiments of the invention, the extraction solvent is selected from ethyl acetate, isopropyl acetate, a supercritical CO₂ and ethanol mixture, a C3 to C5 glycol, a C1 to C5 alcohol, an alcohol / water mixture, a hydrotropic solution, or a mixture thereof. Advantageously, it is an ethanol / water mixture or a hydrotropic solution. More advantageously, it is an ethanol / water mixture. Even more advantageously, this ethanol / water mixture is characterized by an ethanol / water ratio of 9:1 to 7:3 (v / v). And even more advantageously, the moderately polar solvent is an ethanol / water mixture in the proportion of 9:1 (v / v).

[0035] Extraction can be performed under agitation or statically, under reflux, at room temperature, or at a temperature between room temperature and reflux. It can be assisted by ultrasound, microwaves, flash détente, or extrusion, in a plant weight / solvent volume ratio ranging from 1 / 3 to 1 / 30, for a duration of 1 minute to 48 hours. The extraction can be repeated 2 to 3 times.

[0036] The pomace can then be separated from the extract by centrifugation or filtration to obtain a clear, particle-free liquid phase. The liquid phase representing the extract can be more or less concentrated, even resulting in a dry extract. Therefore, the process of preparing Garcinia mangostana extract may include a concentration step.

[0037] In some embodiments, a support may be added during the concentration step in order to obtain an extract of Garcinia mangostana containing 1 to 75% by weight of dry extract.

[0038] The carrier can be maltodextrin, lactose, silica, glycerin, a glycol, a vegetable oil, a hydrotrope, a water / solubilizer or water / surfactant mixture, or any other cosmetically acceptable carrier that solubilizes the extract, preferably of bio-based origin such as bio-based glycols (1,2-pentanediol; 1,3-butanediol; 1,3-propanediol...), esterified fatty acids and also hydrotropes such as alkyl glycosides (Sepiclear, Apyclean, APXC4...).

[0039] In some embodiments, the process for preparing Garcinia mangostana extract includes a decolorization step. Thus, Garcinia mangostana extract can be decolorized, for example, with activated charcoal. Advantageously, Garcinia mangostana extract is not decolorized. Fresh Avena Sativa Juice

[0040] Oats, or Avena sativa L., are annual plants of the grass family (Poaceae) that can reach 1.5 meters in height. Upon germination, the young plant forms a turf and then produces several stems.

[0041] The stem or culm is hollow, a few millimeters in diameter, interrupted at intervals, where the leaves are inserted, by solid diaphragms called nodes. The internodes, initially very short at the base of the stem, become progressively longer.

[0042] The oat fruit or grain is recognized as a medicinal raw material for oral use as a laxative due to its bulking effect, and also for its use in managing cholesterol and type 2 diabetes due to its beta-glucan content. Topically, oat fruit is primarily used in the form of flour. One grade of this flour, called colloidal oat extract, has a monograph in the United States Pharmacopeia (USP 22, 1990). This colloidal extract has emollient and soothing properties and is defined as the powder resulting from the grinding and other processing of the whole grain; this grade corresponds to oat flour. From this same part of the oat, oil used in cosmetics and proteins can also be extracted. These proteins, being insoluble, are not used directly but only after enzymatic or chemical hydrolysis.A more or less extensive hydrolysis process is performed, yielding either oat peptides of varying molecular weights or amino acids, depending on the strength of the hydrolysis. Hydrolyzed oat proteins have been studied for their properties in the cosmetic and dermatological fields. For example, properties have been demonstrated on hair, such as the ability of these peptides to form a film on the hair shaft, penetrate the cuticle, and thus, through the resulting coating effect, provide a conditioning effect.

[0043] Besides its grain, oats are used as animal fodder. Cut young, they provide highly valued green forage. The straw is fed to horses, cows, and sheep, but is not used for human consumption. In traditional medicine, oat straw is used to prepare soothing baths for rheumatic pain, sciatica, and liver ailments. In India, decoctions of common oats were used to help opium addicts wean themselves off drugs. An alcoholic extract prepared from fresh oats has been used in smoking cessation with statistically significant results.

[0044] Oat grass is the subject of an EMEA monograph (Reference EMEA / HMPC / 202966 / 2007) which mentions the use of either the aerial parts harvested before flowering and dried, or a liquid extract (1:5, 45% v / v ethanol) prepared from the fresh aerial parts of the plant harvested during the flowering period. The traditional use of these aerial parts is described for mild mental stress and to promote sleep. According to the literature, the aerial parts of oats are composed of: Flavonoids: ∘ C-glycosyl-flavones of the apigenin type (vitexin, isovitexin...) or luteolin type (orientin, isoorientin, isoscoparin...), ∘ Tricine-type flavones, O-glycosyl flavones, ∘ Flavolignans (salcolins A and B), Bidesmoside steroidal saponins: Avenacosides A and B (aglycone: nuatigenin), Proteins, Other: phenolic compounds (avenanthramides, hydroxycinnamic acids...), sterols, cerebrosides...

[0045] In the present invention, the plant Avena sativa L., as well as its variety Rhea, renamed Rhealba, is referred to in abbreviated form by the term Avena sativa.

[0046] By " Avena sativa "Fresh" oats, as defined in the present invention, refer to the aerial parts of oats, excluding the grains themselves, used fresh or thawed, composed of 30 to 90% water, preferably 40 to 90% water, and even more preferably 40 to 80% water, by weight. It is understood that the aerial parts of oats used to produce the juice have not been dried and are processed quickly after harvesting to minimize water loss. They may be frozen for later processing.

[0047] Preferably, the aerial parts of oats are the aerial parts of oat seedlings.

[0048] The juice of 'Avena sativaA useful ingredient within the framework of the invention is thus a juice from the aerial parts of oats. More particularly, the juice of 'Avena sativa Fraiche is a juice made from the aerial parts of oat seedlings.

[0049] Seedlings represent the part of the plant harvested before heading at the mid-stemming stage, approximately two months after planting, that is, before the appearance of flowers and fruits (or grains). At this stage, the plant lacks pollen proteins and grains.

[0050] The term "aerial parts" refers to the stems, leaves, and flowers, and in the case of seedlings, only the stems and leaves. These aerial parts do not include the fruits (also called grains), and in the case of seedlings, they do not include the flowers. The plant is not dried but may be frozen to preserve its freshness.

[0051] By "juice of 'Avena sativa"Fresh" is understood in the context of the present invention to mean water 'Avina sativa, containing the molecules of interest, without any denaturation. Fresh plants, that is to say, not dehydrated, in particular seedlings, and more specifically the aerial parts of seedlings, are subjected to a thermomechanical treatment consisting of extruding the Avina sativa fresh in an extruder, combined with a heat treatment to inactivate endogenous enzymes and preserve molecules of compounds of interest in their native form, in the absence of solvent, followed by a juice recovery operation.

[0052] It is thus clear that a "juice" is distinct from an "extract." In the preparation of an "extract," the molecules of interest are removed from the plant using a solvent, which can be water, an organic solvent, or a mixture thereof. Obtaining a juice requires no solvent. The juice therefore corresponds to the liquid fraction contained within the plant and extracted from it, in this case by thermomechanical treatment.

[0053] Fresh oat juice (INCI: Avena sativa (OAT) Flower / Leaf / Stem Juice) thus corresponds to the water naturally present in the aerial parts of oats, and more particularly the aerial parts of oat seedlings.

[0054] When fresh plants are pressed using traditional techniques, the plant cell wall sometimes hinders the recovery of certain compounds of interest. Furthermore, the native enzymes present in the plant are easily released and can begin to alter and denature the extracted compounds in the juice: hydrolysis, oxidation, deglycosylation, etc.

[0055] The adaptation of an extrusion technique widely used in food to cook and expand materials, for extraction purposes, has thus made it possible to recover a native juice from the fresh plant without the use of solvents or water in which the active molecules have not been modified or altered by endogenous enzymes.

[0056] Indeed, extrusion allows the plant's cell walls to be completely broken down and the very short heat treatment (a few seconds) allows the enzymes to be neutralized without damaging the molecules of interest present.

[0057] This technique is described in detail in patent application WO 2015 / 040135.

[0058] Depending on the process used to obtain fresh oat juice, particularly juice from the aerial parts of fresh oat seedlings, "extrusion" means a thermomechanical treatment consisting of extruding the fresh plant, particularly the aerial parts of fresh oat seedlings, in an extruder, preferably a twin-screw extruder, combined with a heat treatment.

[0059] Thus, to obtain fresh oat juice, particularly juice from the aerial parts of fresh oat seedlings, extrusion is characterized by passing the fresh plant, particularly the aerial parts of fresh oat seedlings, through a twin-screw extruder composed of: an area for introducing fresh plants, particularly aerial parts of fresh oat seedlings: Feed hopper the main body of the extruder consists of one or more sleeves in which the worm screws (co-rotating or counter-rotating), or screw segments, rotate.

[0060] Preferably, these are several successive adjacent sleeves. Preferably, they are two co-rotating worms. The profile of the screws can vary according to the shape of the screw thread (e.g., trapezoidal, conjugate, single or double) and the pitch. Each of these screws can also have different sections (or segments) which may differ from each other in the shape of the thread and / or the pitch. Optionally, some of the constituent sections of these screws may also correspond to single-lobe or three-lobe mixing elements. at least one filter sleeve which: intervenes, if necessary, for solid / liquid separation; also includes a filtration means, such as a screen; and is located, in particular, at the extruder outlet; heating and cooling means, as the sleeve temperature must be regulated from 60 to 300°C; extruder control means such as: a drive unit consisting of a geared motor and a torque divider, which provide the mechanical power necessary for screw rotation; and control systems that allow for process monitoring and control. The adjustable parameters are: the screw rotation speed and the temperature of each sleeve.

[0061] In a particular embodiment, the extruder is a twin-screw co-rotating and co-penetrating extruder.

[0062] In some embodiments, the process uses an extruder, preferably a twin-screw extruder with several barrels and ending with a filter barrel, allowing the temperature to be varied and at the same time applying intense shearing and mixing of the plant raw material, resulting in the release of a large number of compounds, the destructuring of the material, and also the inhibition of endogenous enzymes by heat treatment.

[0063] The process of preparing fresh oat juice involves extruding fresh or frozen oat plants, specifically the aerial parts of the plants, and more particularly the aerial parts of fresh or even frozen oat seedlings. This is done to extract the juice, which is then collected and purified. Finally, in an optional last step, the collected juice is stabilized.

[0064] According to one variant, the recovered juice can be subjected to a further stabilization, clarification and / or filtration step.

[0065] Fresh oat juice, particularly the juice from the aerial parts of fresh oats or fresh oat seedlings, useful in the context of the invention, is obtained by a thermomechanical treatment comprising or consisting of a crushing operation of the fresh plants, in particular of said aerial parts, by shearing at temperatures between 60°C and 300°C, preferably between 60°C and 150°C, more particularly between 75°C and 140°C, more particularly still between 80°C and 130°C, and even more particularly around 120°C.

[0066] Advantageously, the thermomechanical treatment is implemented in a twin-screw extruder comprising a first zone of co-rotating and co-penetrating twin screws where the crushing of plants, plant parts, seedlings, or seedling parts takes place, and a second zone of separate twin screws where the solid / liquid separation occurs. The flow in the twin-screw zone is generated by a pumping effect and not by frictional forces between the screw and the barrel, as occurs in a single-screw extruder.

[0067] Advantageously, the feeding, transport, mechanical shearing and thermomechanical treatment enabling the crushing of fresh plants and the extraction of juice are carried out in the first zone of the extruder, and the liquid / solid separation operation is carried out in the second zone.

[0068] Advantageously, the first zone comprises several successive sheaths whose temperatures are set to present increasing temperature steps staggered between 60°C and 130°C, and the second zone comprises at least one sheath brought to a temperature between 30°C and 130°C, preferably between 30°C and 100°C.

[0069] Thus, fresh oat plants, particularly the aerial parts of fresh oats, or fresh oat seedlings, particularly the aerial parts of fresh oat seedlings, are extracted by a mechanical extrusion process using a twin-screw extruder at approximately 100 to 130°C, specifically around 120°C. It is at this temperature that the extrusion of flavonoids from the plant material is optimal. The resulting juice can be filtered and undergo ultrafiltration, for example, with a cutoff threshold of 3.5 kDa. In addition to inactivating proteins in the extruder, this filtration removes any remaining traces of protein. Finally, the juice can undergo sterilizing filtration and stabilization in the presence of vegetable glycerin. Extrusion of fresh oat plants, particularly the aerial parts of fresh oat seedlings, yields: good juice yield, good extracted dry matter yield, good flavonoid yield, presence of non-hydrolyzed saponins in the juice.

[0070] The analysis of fresh oat juice obtained by such a process yields the following results: Flavonoids: isovitexin-2''-O-arabinoside, isoorientin-2''-O-arabinoside, content: 2 to 4%, particularly about 2.5% by weight relative to dry matter (0.1 to 1%, particularly about 0.2% by weight relative to pure juice); total sugars: glucose, galactose, fructose, content of 40 to 50% by weight relative to dry matter, particularly about 44%; minerals: Mg (0.3 to 0.4% by weight, particularly about 0.6% relative to dry matter), Ca (0.1 to 0.5% by weight, particularly 27%, relative to dry matter); proteins: no proteins detected in the permeate (<1.2 ppm by electrophoresis); a dry matter content between 2 and 20%, particularly between 4 and 18%, more particularly still between 5 and 15% dry matter by weight, compared to the weight of the juice.

[0071] The association of the present invention typically comprises a mass ratio of dry extract of Garcinia mangostana L. / juice of 'Avena sativa fresh ranging from 0.0002 / 1 to 5000 / 1, preferably ranging from 0.005 / 1 to 1 / 1 or from 0.01 / 1 to 0.5 / 1 or from 0.04 / 1 to 0.16 / 1. COMPOSITIONS

[0072] The present invention also relates to a cosmetic or dermatological composition comprising a combination according to the invention, that is to say, comprising an extract of Garcinia mangostana, a juice of 'Avena sativa fresh, and at least one cosmetically or dermatologically acceptable excipient.

[0073] Garcinia mangostana extract and juice 'Avena sativafresh can be as described above. In the present invention, "cosmetically or dermatologically acceptable" means that which is useful in the preparation of a cosmetic, dermatological composition, which is generally safe, non-toxic and neither biologically nor otherwise undesirable and which is acceptable for cosmetic or dermatological use, in particular by topical application to the skin, in particular on the face.

[0074] In some embodiments, Garcinia mangostana extract and juice of 'Avena sativa Fresh ingredients are the only active ingredients in the cosmetic or dermatological composition.

[0075] The invention preferably relates to cosmetic or dermatological compositions presented in a form suitable for topical application.

[0076] By "topical application" we mean an application on the skin, mucous membranes, particularly on the face.

[0077] Cosmetic or dermatological compositions can thus be presented in the forms which are usually known for topical administration, namely lotions, shampoos, balms, mousses, gels, dispersions, emulsions, sprays, serums, masks, creams or sticks with excipients which, in particular, allow penetration in order to improve the properties and accessibility of the active ingredients.

[0078] The cosmetic or dermatological composition, in addition to Garcinia mangostana extract and juice of 'Avena sativafresh and a cosmetically acceptable excipient, may also contain surfactants, complexing agents, preservatives, antioxidants (such as tocopherols), stabilizing agents, emulsifiers, thickeners, gelling agents, humectants, emollients, trace elements, essential oils, perfumes, colorants, mattifying agents, chemical or mineral filters, moisturizing agents, thermal waters, etc.

[0079] In some embodiments, the cosmetic or dermatological composition includes an extract of the pericarp of the fruit of Garcinia mangostana.

[0080] In some embodiments, the cosmetic or dermatological composition includes a hydro-alcoholic extract of Garcinia mangostana, preferably a hydro-alcoholic extract of the pericarp of the fruit of Garcinia mangostana.

[0081] In some embodiments, the cosmetic or dermatological composition includes a juice of 'Avena sativa fresh, in particular a juice of aerial parts of oats, especially a juice of aerial parts of oat seedlings. Preferably, this juice is obtained by a thermomechanical treatment comprising or consisting of a crushing operation of said fresh plants, in particular the aerial parts, by shearing at temperatures between 60°C and 300°C, preferably between 60°C and 150°C, more particularly between 75°C and 140°C, more particularly still between 80°C and 130°C and even more particularly around 120°C.

[0082] The cosmetic or dermatological composition advantageously includes a juice of 'Avena sativafresh, particularly an aerial part juice of oats or an aerial part juice of oat seedlings, comprising a dry matter content of between 2 and 20% by weight of dry matter, particularly between 4 and 18% by weight, and more particularly between 5 and 15% by weight of dry matter, relative to the weight of the juice.

[0083] The cosmetic or dermatological composition advantageously comprises a hydro-alcoholic extract of Garcinia mangostana, preferably a hydro-alcoholic extract of the pericarp of the Garcinia mangostana fruit and a juice of aerial parts of 'Avena sativafresh, in particular a juice of aerial parts of oat seedlings. The cosmetic or dermatological composition includes in particular from 0.001 to 5% by weight of a dry extract of Garcinia mangostana, preferably from 0.002 to 2% by weight, preferably from 0.005 to 1% by weight, even more preferably from 0.01 to 0.5% by weight of a dry extract of Garcinia mangostana in relation to the total weight of the composition.

[0084] The cosmetic or dermatological composition includes, in particular, approximately 0.01 to 10% by weight of fresh Avena sativa juice relative to the total weight of the composition, specifically approximately 0.1 to 5% by weight, specifically approximately 0.2 to 5% by weight, more specifically 0.3 to 4% by weight, even more specifically 0.4 to 3% by weight, and even more specifically 0.5 to 2% by weight of fresh Avena sativa juice relative to the total weight of the composition, or even approximately 1% by weight of fresh Avena sativa juice relative to the total weight of the composition.

[0085] The cosmetic or dermatological composition includes, in particular: from 0.001 to 5% by weight of a dry extract of Garcinia mangostana, preferably from 0.002 to 2% by weight, more preferably from 0.005 to 1% by weight, even more preferably from 0.01 to 0.5% by weight of dry extract of Garcinia mangostana relative to the total weight of the composition, and from about 0.01 to 10% by weight of fresh Avena sativa juice, in particular from about 0.1 to 5% by weight, in particular from about 0.2 to 5% by weight, more particularly from 0.3 to 4% by weight, even more particularly from 0.4 to 3% by weight, and even more particularly from 0.5 to 2% or even about 1% by weight of fresh Avena sativa juice, relative to the total weight of the composition.

[0086] Preferably, fresh Avena sativa juice is present in the cosmetic or dermatological composition at a content of approximately 0.5% by weight relative to the total weight of the composition.

[0087] Also preferred, fresh Avena sativa juice is present in the cosmetic or dermatological composition according to the invention at a content of about 1% by weight relative to the total weight of the composition. USES AND METHODS

[0088] The invention also relates to an association comprising an extract of Garcinia mangostana and a juice of 'Avena sativa fresh or a cosmetic or dermatological composition comprising such a combination and at least one cosmetically or dermatologically acceptable excipient, for its use in the treatment of inflammation induced by C . acnes.

[0089] Garcinia mangostana extract, juice 'Avena sativa fresh and the cosmetic or dermatological composition including such an association may be as described above.

[0090] The invention also relates to the use of a combination comprising an extract of Garcinia mangostana and a juice of 'Avena sativa fresh for the preparation of a cosmetic or dermatological composition intended for the treatment of inflammation induced by C . acnes.

[0091] The invention also relates to the use of a combination comprising a Garcinia mangostana extract and a juice of 'Avena sativa fresh or of a cosmetic or dermatological composition comprising such an association and at least one cosmetically or dermatologically acceptable excipient, in the treatment of inflammation induced by C . acnes.

[0092] The invention also relates to the use of a cosmetic or dermatological composition comprising a Garcinia mangostana extract and a juice of 'Avena sativa fresh for the preparation of a medicinal product intended for the treatment of inflammation induced by C . acnes.

[0093] The invention also relates to a method for treating inflammation induced by C . acnes including the administration to a person in need of an effective amount of a combination comprising a Garcinia mangostana extract and a juice of 'Avena sativa fresh or of a cosmetic or dermatological composition comprising such an association and at least one cosmetically or dermatologically acceptable excipient.

[0094] The invention also relates to an association comprising an extract of Garcinia mangostana and a juice of 'Avena sativa fresh or a cosmetic or dermatological composition comprising such an association and at least one cosmetically or dermatologically acceptable excipient, for its use in the treatment of acne or acne-prone skin.

[0095] The invention also relates to the use of a combination comprising an extract of Garcinia mangostana and a juice of 'Avena sativa fresh for the preparation of a cosmetic or dermatological composition intended for the treatment of acne or acne-prone skin.

[0096] The invention also relates to the use of a combination comprising a Garcinia mangostana extract and a juice of 'Avena sativa fresh or of a cosmetic or dermatological composition comprising such an association and at least one cosmetically or dermatologically acceptable excipient, in the treatment of acne or acne-prone skin.

[0097] The invention also relates to the use of a cosmetic or dermatological composition comprising a Garcinia mangostana extract and a juice of 'Avena sativa fresh for the preparation of a medicine intended for the treatment of acne or acne-prone skin.

[0098] The invention also relates to a method for treating acne or acne-prone skin comprising administering to a person in need an effective amount of a combination comprising a Garcinia mangostana extract and a juice of 'Avena sativa fresh or of a cosmetic or dermatological composition comprising such an association and at least one cosmetically or dermatologically acceptable excipient.

[0099] The following examples illustrate the invention without limiting its scope. EXAMPLES Example 1: Extraction at reflux at 90% ethanol

[0100] 377 grams of ground, dried pericarp of Garcinia mangostana were extracted under reflux with stirring using 3.8 liters of a 90:10 (v / v) ethanol / water mixture for 1 hour in a reactor. The extract was then filtered through a K900 filter plate, and the solvent was evaporated to obtain 100 grams of an orange powder with a mass yield of 26%. The resulting dry extract contained 15.9% by weight of alpha-mangostin. Example 2: Extraction à reflux à l'éthanol 90% suivie d'une put sur support

[0101] 200 grams of ground, dried Garcinia mangostana pericarp were extracted under reflux with stirring using 2 liters of a 90:10 (v / v) ethanol / water mixture for 1 hour in a reactor. The extract was then filtered through a K900 filter plate and subsequently dried over maltodextrin to obtain 142 grams of extract in the form of an orange-beige powder. The extract contains 75% maltodextrin and 3.5% alpha-mangostin by weight of the extract. Example 3: Extraction at reflux at 90% ethanol on one set on support

[0102] 1000 grams of ground, dried Garcinia mangostana pericarp were extracted under reflux with stirring using 10 liters of a 90:10 (v / v) ethanol / water mixture for 1 hour in a reactor. The extract was then filtered through a K900 filter plate and subsequently dried over 1,2-pentanediol to obtain 747 grams of extract as a dark, viscous liquid. The extract contained 70% 1,2-pentanediol and 4.9% alpha-mangostin by weight of the extract. Example 4: Hexane reflux extraction

[0103] Seventeen grams of ground, dried Garcinia mangostana pericarp were extracted under reflux with stirring using 170 milliliters of hexane for 1 hour in a reactor. The extract was then filtered through a K900 filter plate, and the solvent was evaporated to obtain 200 milligrams of an orange-yellow paste with a mass yield of 1.2%. The resulting dry extract contained 75.0% alpha-mangostin by weight. Example 5: Ultrasonic-assisted extraction with 96% ethanol

[0104] 36 grams of ground, dried Garcinia mangostana pericarp were contacted with 350 milliliters of 96% ethanol and then extracted using ultrasound (20 kHz) for three one-minute intervals at 100% amplitude. The extract was then filtered through a K900 filter plate, and the solvent was evaporated to obtain 7.9 grams of a purplish-red powder with a mass yield of 22%. The resulting dry extract contained 16.4% alpha-mangostin by weight. Example 6: Reflux extraction with 96% ethanol

[0105] Twenty grams of ground, dried pericarp of Garcinia mangostana were extracted under reflux with stirring using 200 milliliters of 96% ethanol for one hour in a reactor. The extract was then filtered through a K900 filter plate, and the solvent was evaporated to obtain 5.3 grams of a purplish-red powder with a mass yield of 26%. The resulting dry extract contained 16.0% by weight of alpha-mangostin. Example 7: Hydrotropic extraction with a 1.5M aqueous heptylglucoside solution

[0106] 26 grams of ground, dried Garcinia mangostana pericarp were extracted for 2 hours at 40°C with stirring using 260 milliliters of a 1.5M aqueous heptylglucoside solution. After filtration through a K900 filter plate, the filtrate was acidified to pH 2 and then diluted with 11 volumes of water acidified to pH 2. After centrifugation, the pellet was collected and dried to obtain an orange paste with a mass yield of 7.3%. The resulting dry extract contained 17.0% by weight of alpha-mangostin. Example 8: Hydrotropic extraction with a 25% aqueous solution of butyl xylosides

[0107] Twenty grams of ground, dried Garcinia mangostana pericarp were extracted for two hours at room temperature with stirring using 200 milliliters of a 25% (w / w) aqueous butyl xylosides solution. After filtration through a K900 filter plate, the filtrate was diluted with two volumes of water. After centrifugation, the pellet was collected. The supernatant was diluted with two volumes of water. After centrifugation, this pellet was again collected and combined with the previous pellet to obtain the dry extract of Garcinia mangostana as a brown powder with a mass yield of 4.9%. The dry extract obtained contains 53.0% (w / w) alpha-mangostin. Example 9: Hydrotropic extraction with an aqueous solution of butyl xylosides (APXC4) assisted by extrusion

[0108] 670 grams of dried Garcinia mangostana pericarps are introduced into the first sleeve of a Clextral BC45 twin-screw extruder at a flow rate of 40 kg / h. A 26% wt. aqueous solution of butyl xylosides is then introduced at a flow rate of 120 kg / h.

[0109] The temperature applied to the various sleeves is 60°C. After one minute, the Garcinia mangostana pericarp extract is collected at the extruder outlet using a filter sleeve that allows solid / liquid separation. After clarification, the solution is diluted with 2 volumes of water. After centrifugation, the pellet is collected. The supernatant is diluted with 2 volumes of water. After centrifugation, the pellet is collected again and combined with the previous pellet to obtain the dry Garcinia mangostana extract in the form of an orange paste with a mass yield of 0.4%. The dry extract obtained contains 50.0% alpha-mangostin by weight. Example 10: Extraction by supercritical CO2

[0110] 470 grams of ground, dried pericarp of Garcinia mangostana were extracted for 2 hours at 50°C and 50 bar using supercritical CO2 at a flow rate of 10 kg / h. The extract was then solubilized in ethanol and filtered through a K900 filter plate. The solvent was evaporated to obtain 3.4 grams of an orange-yellow paste with a mass yield of 0.7%. The resulting dry extract contained 9.45% alpha-mangostin by weight.

[0111] The pomace (466 grams) was then extracted for 1 hour at 50°C and 50 bar using supercritical CO2 with ethanol as a co-solvent (flow rates of 10 kg / h and 1 kg / h, respectively). The extract was filtered through a K900 filter plate, and the solvent was evaporated to obtain 2.3 grams of an orange-yellow paste with a mass yield of 0.5%. The resulting dry extract contained 22.3% alpha-mangostin by weight. Example 11: Obtaining fresh oat juice by thermomechanical treatment

[0112] 12.75 kg of fresh, thawed (24h at 2°C) oat aerial parts ( Avena sativa L.) harvested with a silage harvester after 2 months of growth (oat seedlings) were introduced into the first sleeve of a CLEXTRAL BC45 twin-screw extruder with co-rotating and copemetrating screws, which has 5 of them. The temperature applied to the different sleeves is 30°C / 120°C / 120°C / 120°C / 60°C.

[0113] The process flow diagram is as follows (total duration of the extrusion step = 20 minutes; processing rate 38 kg of plants / h and 22 kg of juice / h): Fresh aerial parts → Extrusion 120°C → Extruded pomace → Raw juice (yield 57.2% (w / w)) → Clarification → Sterilizing filtration Clear juice containing 11% dry matter (DM) (yield 53.1% (w / w)) →5.8% DM / fresh plant

[0114] After extrusion, 57.2% juice (w / w) was obtained relative to the initial material. Clarification and sterilizing filtration steps were then carried out to obtain a clear juice, with a final juice yield of 53.1% containing 11% dry matter by weight, i.e., a dry matter extracted yield of 5.8% (w / w).

[0115] The yield of juice obtained by pressing (crushing-pressing-filtering) the same raw material is 50%, containing 4.5% dry matter by weight, i.e. a yield of 2.25% (w / w).

[0116] Extrusion technology therefore yields more juice, and juice richer in compounds, particularly bioactive compounds. Indeed, the flavonoid content (by weight) of the juice obtained in this example is 0.26%, whereas it is only 0.02% in juice obtained by pressing the same raw material. The flavonoid content has thus been increased tenfold in this case. These results are presented in Table 1.

[0117] It can also be noted that hot extrusion is beneficial for flavonoid content: the temperature allows for the extraction of more compounds (including 4 times more flavonoids) and for obtaining native molecules, not denatured by enzymes.

[0118] This is also observed with oat saponins, avenacosides, which are rapidly deglycosylated by pressing. Native molecules are recovered only by thermomechanical treatment: juices obtained by extrusion at 120°C and 200°C do indeed contain avenacosides (A and B) at levels of 89 mg and 93 mg per 100 g of dry matter (DM).

[0119] They were not degraded by endogenous deglucosidases. Table 1 % Flavonoids (% by weight) Technical Settings Juice Rdt * MS (% by Weight) Rdt MS / pl MS / juice Fresh material Avenacosides % Pressing Crushing, (1) 51 3,78 1,94 0,44 0,02 0,01 Desgluco avenacosides Extrusion 25°C 59,70 7,50 4,47 0,80 0,06 0,04 0% 1200C 53,13 11 5,84 2,40 0,26 0,15 89 mg %g ES 200°C 48,07 10 4,81 2,30 0,22 0,12 93 mg %g ES H2O extraction 1H reflux 3,10 1,10 0,03 * : after filtration; (1) : Crushing, wine press and filtration Example 12: Biological properties of the association according to the invention

[0120] The aim of this study is to evaluate the anti-inflammatory properties of a Garcinia mangostana extract and fresh Avena sativa juice on inflammation induced by C . acnes.

[0121] To address this hypothesis, concentrations of Garcinia mangostana extract, fresh Avena sativa juice, and their combination are evaluated on the induced immuno-inflammatory cascade in response to C . acne in planktonic culture upstream of the TH1 and Th17 pathways, on the production of pro-inflammatory cytokines by dendritic cells derived from monocytes. Method :

[0122] The experiments are conducted on co-cultures of immature dendritic cells derived from monocytes, at a final concentration of 1.105 cells / ml / well of C . acne planktonic.

[0123] Monocytes are purified from human blood by negative selection (The Easy Step ™ Human Monocyte Enrichment Kit, StemCell).

[0124] On Day 0, monocytes are incubated in a differentiation medium (Gibco Roswell Park Memorial Institute (RPMI), 10% v / v decomplemented Fetal Bovine Serum (FBS) (heated to 56°C for 30 min), 50 ng / ml IL-4, and 100 ng / ml Recombinant Human Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)). On Day 3 of culture, half of the medium is replaced with fresh medium. On Day 6, immature dendritic cells are characterized by flow cytometry and stimulated with a suspension of C . acnes. This culture is prepared by Fonderephar (Toulouse, France) in a suitable culture medium, Columbia agar + 5% sheep blood (COS). A 20 ml preparation of C. acne is made extemporaneously in BHI broth at approximately 54% transmission at 640 nm.

[0125] The enumeration is carried out by dilution to 1 / 10, in the same broth, up to the dilution 10 -6< .

[0126] Spread 2 x 100µl of the 10⁻⁵ and 10⁻⁶ dilutions onto COS agar. Incubate for 72 hours under anaerobic conditions at 36°C.

[0127] Stimulation of monocyte-derived dendritic cells by planktonic culture of C. acnes is carried out at an infection multiplicity factor (MOI) close to 100; MOI = C . acnes / cellules dendritiques dérivées des monocytes .

[0128] The Garcinia mangostana extract used in this study is prepared according to example 1.

[0129] It is diluted in DMSO and tested at 1.25; 2.5 and 10 µg / ml.

[0130] Fresh Avena sativa juice is prepared according to example 11, it is diluted in the culture medium, it is tested at 10, 20 and 70 µg / ml.

[0131] A positive control to inhibit the production of inflammatory cytokines is also tested in this study, namely Dexamethasone at a concentration of 300 ng / ml, solubilized in water.

[0132] The supernatants are recovered after 24 hours of stimulation.

[0133] The results are averaged from 3 independent experiments.

[0134] Two cytokines are evaluated in this study: IL-6 and IL-12p40, these cytokines are quantified in multiplex via the Luninex technology (Bioplex 200, Biorad). Results :

[0135] The effects of an extract of Garcinia mangostana and fresh Avena sativa juice, alone or in combination, on the production of interleukin 6 (IL-6) by dendritic cells derived from monocytes, stimulated with planktonic cultures of C. acne are presented in Table 2 below. Table 2 Products Concentration Average IL-6 production (%) % inhibition Statistics No stimulation - 0 - Stimulation Culture C. acne 100 0 Dexamethasone 300 ng / ml 52,6 45,9 P<0,001 Garcinia mangostana extract (GM) 1.25 µg / ml 84,1 NS 2.5 µg / ml 67,8 32,2 P<0,01 10 µg / ml 34,7 62,3 P<0,001 Fresh Avena sativa juice 10 µg / ml 76,7 NS 20 µg / ml 84,3 NS 70 µg / ml 90,6 NS Extract G. m + Fresh Avena sativa juice 1.25 µg / ml + 10 µg / ml 71,3 28,7 P<0,05 2.5 µg / ml + 20 µg / ml 61,4 38 ,6 P<0,001 10 µg / ml + 70 µg / ml 34,2 63,3 P<0,001 NS: not significant.

[0136] Without stimulation, monocyte-derived dendritic cells do not produce IL-6. However, planktonic culture of C. acne significantly induced IL-6 production by monocyte-derived dendritic cells. The positive control, dexamethasone at 300 ng / ml, significantly inhibited this production; these expected results validate this test.

[0137] Garcinia mangostana extract at 1.25 µg / ml does not alter IL-6 release compared to the C. culture stimulation condition. acne,Conversely, at concentrations of 2.5 µg / ml and above, Garcinia mangostana extract significantly inhibits IL-6 production by monocyte-derived dendritic cells. Fresh Avena sativa juice, at all tested concentrations, had no effect on IL-6 production by monocyte-derived dendritic cells. In contrast, the combination of Garcinia mangostana extract at 1.25 µg / ml and fresh Avena sativa juice at 10 µg / ml significantly inhibited IL-6 production with a synergistic effect. Similarly, at intermediate concentrations, the combination of Garcinia mangostana extract and fresh Avena sativa juice revealed a statistically greater inhibitory effect (P<0.001) compared to the agents used individually.

[0138] The effects of an extract of Garcinia mangostana and fresh Avena sativa juice, alone or in combination, on the production of interleukins 12p40 (IL-12p40) by dendritic cells derived from monocytes, stimulated with planktonic cultures of C. acne are presented in Table 3 below. Table 3 Products Concentration Average production of IL-12p40 (%) % inhibition Statistics No stimulation - 0 - Stimulation Culture C . acne 100 0 Dexamethasone 300 ng / ml 49,4 50,0 P<0,001 Garcinia mangostana extract (GM) 1.25 µg / ml 89,9 NS 2.5 µg / ml 78,6 21,4 P<0,05 10 µg / ml 57,2 41,8 P<0,001 Fresh Avena sativa juice 10 µg / ml 78,4 NS 20 µg / ml 87,1 NS 70 µg / ml 87,4 NS Extract G. m + Fresh Avena sativa juice 1.25 µg / ml + 10 µg / ml 84,7 NS 2.5 µg / ml + 20 µg / ml 71,9 28,1 P<0,01 10 µg / ml + 70 µg / ml 50,6 48,4 P<0,001 NS: not significant.

[0139] Without stimulation, monocyte-derived dendritic cells do not produce IL-12p40. However, planktonic culture of C . acne significantly induced IL-12p40 production by monocyte-derived dendritic cells. The positive control, dexamethasone at 300 ng / ml, significantly inhibited this production; these expected results validate this test.

[0140] Garcinia mangostana extract at 1.25 µg / ml does not alter IL-12p40 release compared to the culture stimulation condition. C . acne,Conversely, at concentrations of 2.5 and 10 µg / ml, Garcinia mangostana extract significantly inhibits IL-12p40 production by monocyte-derived dendritic cells by 21.4% and 41.8%, respectively. Fresh Avena sativa juice, at all tested concentrations, had no effect on IL-6 production by monocyte-derived dendritic cells. In combination, Garcinia mangostana extract at 2.5 µg / ml and fresh Avena sativa juice at 20 µg / ml significantly inhibit (28.1%) IL-12p40 production by monocyte-derived dendritic cells, exhibiting a synergistic effect. Similarly, Garcinia mangostana extract at 10 µg / ml and fresh Avena sativa juice at 70 µg / ml significantly inhibit (48.4%) the production of IL-12p40 by monocyte-derived dendritic cells with a synergistic effect.

[0141] In conclusion, the inventors highlight that fresh Avena sativa juice taken alone has no anti-inflammatory effect, and that Garcinia mangostana extract alone exhibits relatively modest anti-inflammatory activity in this model by inhibiting the production of two interleukins. However, the inventors demonstrate a synergistic effect on anti-inflammatory activity when these two agents are combined.

Claims

1. An association comprising an extract of Garcinia mangostana and fresh Avena sativa juice.

2. The association according to claim 1, characterized in that the Garcinia mangostana extract is a pericarp extract of the Garcinia mangostana fruit.

3. The association according to claim 1 or 2, characterized in that the Garcinia mangostana extract is a hydro-alcoholic extract.

4. The association according to any one of claims 1 to 3, characterized in that the fresh Avena sativa juice is an oat aerial parts juice, in particular an oat seedling aerial parts juice.

5. The association according to any one of claims 1 to 4, characterized in that the fresh Avena sativa juice, particularly the juice from the aerial parts of fresh oats or of fresh oat seedlings, is obtained by a thermomechanical treatment comprising or consisting of a grinding operation of the fresh plants, in particular of said aerial parts, by shearing at temperatures comprised between 60°C and 300°C, preferably between 60°C and 150°C, more particularly between 75°C and 140°C, more particularly still between 80°C and 130°C and even more particularly around 120°C.

6. The association according to any one of claims 1 to 5, characterized in that the fresh Avena sativa juice, particularly the juice from the aerial parts of fresh oats or of fresh oat seedlings, comprises a dry matter content comprised between 2 and 20% dry matter, particularly between 4 and 18%, more particularly between 5 and 15% dry matter by weight, relative to the weight of the juice.

7. The association according to any one of claims 1 to 6, for use in the treatment of inflammation induced by C. acnes.

8. The association according to any one of claims 1 to 6, for use in the treatment of acne-prone skin.

9. A cosmetic or dermatological composition comprising an association according to any one of claims 1 to 6 with at least one cosmetically or dermatologically acceptable excipient.

10. The composition according to claim 9, characterized in that it comprises from 0.001% to 5%, preferably from 0.005% to 1% of Garcinia mangostana extract by weight of dry extract relative to the total weight of the composition.

11. The composition according to claim 9 or 10, characterized in that the fresh Avena sativa juice, particularly the juice of the aerial parts of fresh oats or of fresh oat seedlings, is present in the cosmetic or dermatological composition at a content of about 0.1 to 10% by weight, particularly about 0.2 to 5% by weight, more particularly 0.5 to 2% by weight, or even about 1% by weight, relative to the total weight of the composition.

12. The composition according to any one of claims 9 to 11, characterized in that it is in a form suitable for topical application.

13. The composition according to any one of claims 9 to 12, for use in the treatment of inflammation induced by C. acnes.

14. The composition according to any one of claims 9 to 13, for use in the treatment of acne-prone skin.